Glaxo’s Ebola Vaccine to Be Tested for Safety in Humans
This article is for subscribers only.
U.S. scientists will begin enrolling patients next week in safety trials of GlaxoSmithKline Plc’s experimental Ebola vaccine as the death toll from the disease rises in West Africa.
The National Institutes of Health’s Vaccine Research Center got approval from the Food and Drug Administration to start the Phase 1 trial, Michael Kurilla, director of the Office of Biodefense, Research Resources and Translational Research, said yesterday in a telephone interview. A Phase 1 trial is the first test of a therapy in humans to assess safety and whether it works similarly to how it does in animals.